Clinical Trial Update: A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant [Phase 3]

View source ↗

Summary

Phase 3 trial comparing daratumumab plus lenalidomide versus lenalidomide alone as maintenance in newly diagnosed multiple myeloma patients who are MRD-positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-20